Summary by Moomoo AI
WuXi Biologics (Cayman) Inc. announced a series of senior management changes, including the appointment of Mr. Liu Min as the new CEO and executive director effective July 31, 2024. Mr. Liu will be responsible for leading the company with a focus on innovation, strategic partnerships, operational excellence, and creating long-term value for stakeholders. He has previously held executive positions at Innovent Biologics and Roche, and has extensive industry experience and leadership skills. Dr. Li Yiping, the current CEO and executive director, will step down as CEO and transition to a non-executive director role on the same day, while continuing to serve as chairman of the board to ensure a smooth transition. In addition, Dr. Ann Li Lee and Dr. Krishnan Viswanadhan will also resign from their independent non-executive director positions. The board thanks Dr. Li and the two Drs. for their contributions during their tenure and welcomes Mr. Liu's arrival, looking forward to his leadership in achieving new milestones for the company.